COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Viromed Medical AG enters into a distribution partnership with TriPart for the market launch of ViroCAP® and PulmoPlas® in Turkey
Viromed Medical AG partners with TriPart for market launch of ViroCAP® and PulmoPlas® in Turkey. New distribution agreement to introduce innovative medical technology products in Q1 2026 -
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Viromed Medical AG expects dynamic growth and announces forecast for 2025 and 2026
Viromed Medical AG expects dynamic growth with revenue forecasted to reach around EUR 8-10 million in 2025 and around EUR 80 million in 2026. The EBIT margin is expected to be in the double-digit range from 2026 onwards -
-
-
COMMUNIQUÉ DE PRESSE
Viromed Medical AG: Cold plasma technology shows potential to significantly reduce deaths in ventilated patients
Viromed Medical AG's cold plasma technology shows potential to significantly reduce deaths in ventilated patients according to preclinical study, addressing a critical issue in intensive care medicine
